1[1]Fou A,Schnabel F R,Hamele-Bena D,et al.Long-term outcomes of malignant phyllodes tumors patients:an institutional experience.Am J Surg,2006,192:492-495.
2[2]Roa J C,Tapia O,Carrasco P,et al.Prognostic factors of phyllodes tumor of the breast.Pathol Int,2006,56:309-314.
3[3]Asoglu O,Ugurlu M M,Blanchard K,et al.Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors.Ann Surg Oncol,2004,11:1011-1017.
4[4]Kuijper A,Buerger H,Simon R,et al.Analysis of the progression of fibroepithelial tumours of the breast by PCR based clonality assay.JP athol,2002,197:575-581.
5[5]Wang Z C,Buraimoh A,Iglehart J D,et al.Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.Breast Cancer Res Treat,2006,97:301-309.
6[6]Ben Hassouna J,Dama k T,Gamoudi A,et al.Phyllodes tumors of the breast:a case series of 106 patients.Am J Surg,2006,192:141-147.
5Hawkins RE,Schofiel JB,Wiltshaw E,et al.Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes[J].Cancer,1992,69(9):2271-2275.
6Cheng SP,Chang YC,Liu TP,et al.Phyllodes tumor of the breast:the challenge persists[J].World J Surg,2006,30(7):1414-1421.
7Roa JC,Tapia 0,Carrasco P,et al.Prognostic factors of phyllodes tumor of the breast[J].Pathol Inter,2006,56(2):309-314.
